Dual-modified liposome codelivery of doxorubicin and vincristine improve targeting and therapeutic efficacy of glioma. (1st January 2017)

• Record Type: Journal Article
• Authors: Zhang, Yue; Zhai, Meifang; Chen, Zhijiang; Han, Xiaoyang; Yu, Fanglin; Li, Zhiping; Xie, Xiangyang; Han, Cuiyan; Yu, Lian; Yang, Yang; Mei, Xingguo
• Is Part Of: Drug delivery. Volume 24:Number 1(2017)
• Page Start: 1045
• Page End: 1055
• Publication Date: 2017-01-01
• Subjects: T7 peptide -- DA7R peptide -- brain targeted drug delivery -- glioma -- doxorubicin -- vincristine; Drug delivery systems -- Periodicals; Drug targeting -- Periodicals; 615.05
• DOI: 10.1080/10717544.2017.1344334
• Languages: English
• ISSNs: 1071-7544

Abstract

Abstract: Therapeutic outcome for the treatment of glioma was often limited due to drug resistance and low permeability of drug across the multiple physiological barriers, including the blood-brain barrier (BBB), and the blood-tumor barrier (BTB). In order to overcome these hurdles, we designed T7 and D A7R dual peptides-modified liposomes (abbreviated as T7/ D A7R-LS) to efficiently co-delivery doxorubicin (DOX) and vincristine (VCR) to glioma in this study. T7 is a seven-peptide ligand of transferrin receptors (TfR) capable of circumventing the BBB and then targeting glioma. D A7R is a d -peptide ligand of vascular endothelial growth factor receptor 2 (VEGFR 2) overexpressed on angiogenesis, presenting excellent glioma-homing property. By combining the dual-targeting delivery effect, the dual-modified liposomes displayed higher glioma localization than that of single ligand-modified liposomes or free drug. After loading with DOX and VCR, T7/ D A7R-LS showed the most favorable antiglioma effect in vivo . In conclusion, this dual-targeting, co-delivery strategy provides a potential method for improving brain drug delivery and antiglioma treatment efficacy.